share_log

【港股通】开拓药业-B(09939)上涨4.74% 近日福瑞他恩III期临床试验完成首例患者入组

[Hong Kong Stock Exchange] pioneering Pharmaceutical Industry-B (09939) rose 4.74% recently, the first patient in the group was enrolled after the completion of the phase III clinical trial of Freitain.

鳳凰網港股 ·  Jan 6, 2022 10:16

Phoenix New Media Hong Kong stock | Development Pharmaceutical-B (09939) shares rebounded higher today, rising 4.74% to HK $11.96 with a turnover of HK $26.6 million.

The company previously announced that the Chinese registered phase III clinical trial of KX-826, a self-developed and potentially the world's first topical drug for the treatment of male androgenic alopecia (AGA), completed its first patient enrollment and administration on December 31, 2021. On November 24, 2021, the company announced that China's State Drug Administration (NMPA) had agreed to conduct the phase III clinical trial. Freitain is the first androgen receptor (AR) antagonist in the world to enter a registered phase III clinical trial for AGA treatment.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment